Vanguard Group Inc Entrada Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,129,623 shares of TRDA stock, worth $19.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,129,623

Previous 1,078,908 4.7%

Holding current value

$19.5 Million

Previous $15.3 Million 5.29%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.85 - $16.45 $600,972 - $834,261	50,715 Added 4.7%	1,129,623 $16.1 Million
Q1 2024 May 10, 2024	BUY	$11.58 - $17.0 $159,132 - $233,614	13,742 Added 1.29%	1,078,908 $15.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.36 - $16.99 $509,484 - $761,984	44,849 Added 4.4%	1,065,166 $16.1 Million
Q3 2023 Nov 14, 2023	BUY	$13.61 - $18.01 $143,830 - $190,329	10,568 Added 1.05%	1,020,317 $16.1 Million
Q2 2023 Aug 14, 2023	BUY	$11.02 - $18.01 $893,545 - $1.46 Million	81,084 Added 8.73%	1,009,749 $15.3 Million
Q1 2023 May 15, 2023	BUY	$9.58 - $16.2 $80,586 - $136,274	8,412 Added 0.91%	928,665 $13.5 Million
Q4 2022 Feb 10, 2023	BUY	$13.52 - $22.89 $677,433 - $1.15 Million	50,106 Added 5.76%	920,253 $12.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.65 - $15.76 $1.04 Million - $1.7 Million	107,783 Added 14.14%	870,147 $13.7 Million
Q2 2022 Aug 12, 2022	BUY	$5.49 - $12.94 $1.82 Million - $4.3 Million	331,960 Added 77.13%	762,364 $9.29 Million
Q1 2022 May 13, 2022	BUY	$7.99 - $16.93 $43,561 - $92,302	5,452 Added 1.28%	430,404 $4.04 Million
Q4 2021 Feb 14, 2022	BUY	$13.7 - $35.0 $5.82 Million - $14.9 Million	424,952 New	424,952 $7.27 Million

Others Institutions Holding TRDA

# of Institutions

Shares Held

27.8M

Call Options Held

100

Put Options Held

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $540M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Entrada Therapeutics, Inc. Transaction History